We are working to improve the lives of those with NF.
NFlection Therapeutics (pronounced inflection) is a venture backed biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. NF1 results in the growth of tumors on nerves, and is one of the most commonly inherited neurological disorders, affecting approximately 1 in 4500 people. NFlection has partnered with key leaders in the field of Neurofibromatosis. We plan to announce our lead program in fall 2018.
Copyright © 2017 NFlection Therapeutics, Inc. All Rights Reserved